Dehydrocrenatidine Is a Novel Janus Kinase Inhibitor
Open Access
- 1 April 2015
- journal article
- research article
- Published by Elsevier in Molecular Pharmacology
- Vol. 87 (4) , 572-581
Abstract
Janus kinase (JAK) 2 plays a pivotal role in the tumorigenesis of signal transducers and activators of transcription (STAT) 3 constitutively activated solid tumors. JAK2 mutations are involved in the pathogenesis of various types of hematopoietic disorders, such as myeloproliferative disorders, polycythemia vera, essential thrombocythemia, and primary myelofibrosis. Thus, small-molecular inhibitors targeting JAK2 are potent for therapy of these diseases. In this study, we screened 1,062,608 drug-like molecules from the ZINC database and 2080 natural product chemicals. We identified a novel JAK family kinase inhibitor, dehydrocrenatidine, that inhibits JAK-STAT3–dependent DU145 and MDA-MB-468 cell survival and induces cell apoptosis. Dehydrocrenatidine represses constitutively activated JAK2 and STAT3, as well as interleukin-6–, interferon-α−, and interferon-γ–stimulated JAK activity, and STAT phosphorylation, and suppresses STAT3 and STAT1 downstream gene expression. Dehydrocrenatidine inhibits JAKs-JH1 domain overexpression–induced STAT3 and STAT1 phosphorylation. In addition, dehydrocrenatidine inhibits JAK2-JH1 kinase activity in vitro. Importantly, dehydrocrenatidine does not show significant effect on Src overexpression and epidermal growth factor–induced STAT3 activation. Our results indicate that dehydrocrenatidine is a JAK-specific inhibitor.Keywords
This publication has 51 references indexed in Scilit:
- Search for β2 Adrenergic Receptor Ligands by Virtual Screening via Grid Computing and Investigation of Binding Modes by Docking and Molecular Dynamics SimulationsPLOS ONE, 2014
- Brevilin A, a Novel Natural Product, Inhibits Janus Kinase Activity and Blocks STAT3 Signaling in Cancer CellsPLOS ONE, 2013
- New Substructure Filters for Removal of Pan Assay Interference Compounds (PAINS) from Screening Libraries and for Their Exclusion in BioassaysJournal of Medicinal Chemistry, 2010
- Targeting Inflammatory Pathways for Prevention and Therapy of Cancer: Short-Term Friend, Long-Term FoeClinical Cancer Research, 2009
- Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancerBreast Cancer Research, 2007
- A t(8;9) translocation with PCM1-JAK2 fusion in a patient with T-cell lymphomaLeukemia, 2006
- Electrostatics of nanosystems: Application to microtubules and the ribosomeProceedings of the National Academy of Sciences, 2001
- Stat3 as an OncogeneCell, 1999
- Induction of epithelial tubules by growth factor HGF depends on the STAT pathwayNature, 1998
- Molecular cloning of APRF, a novel IFN-stimulated gene factor 3 p91-related transcription factor involved in the gp130-mediated signaling pathwayCell, 1994